New edition - 24/05/2019 Tumour metastasis Cancer is usually not curable when metastases have formed in the body. Metastases are often resistant to drugs that have successfully eliminated the primary tumour. The basic features of the complex process of metastasis are now known, but many details still remain elusive. Intensive research activities are focusing on new therapeutic concepts aimed at developing effective anti-metastatic therapies.https://biopro-v9-test-gi.xanium.io/en/article/dossier/tumour-metastasis
Expert interview - 13/05/2019 Innovation management in the life sciences – Inova DE provides insights Personalized medicine, medical technology, digital health and artificial intelligence are revolutionizing diagnostics and product development. Analyses are becoming faster and more precise, and data volumes can now be networked and used effectively. The goal of improving people's quality of life is within reach, and this will also strengthen Germany’s future viability. However, not every good idea can be turned into a marketable commodity.…https://biopro-v9-test-gi.xanium.io/en/article/news/innovation-management-in-the-life-sciences-inova-de-provides-insights
Article - 23/04/2019 How can care infrastructures benefit from digitization? The pilot project NeCTra (Networking - Care - Transparency) investigates how care processes within an urban social environment can be improved by using digital technologies. The goal is to bring together all partners and institutions in real time so that people in need of care and those seeking advice receive appropriate support more quickly.https://biopro-v9-test-gi.xanium.io/en/article/news/how-can-care-infrastructures-benefit-from-digitization
Article - 18/03/2019 EHR and PHR: digital records in the German healthcare system EHRs, i.e. electronic health records (German: Patientenakte, ePA), are hailed as the key to increasing the quality of care. The Appointment Service and Supply Act (TSVG), adopted on 14th March 2019, requires the German statutory health insurance funds to provide policyholders with electronic health records from 1st January 2021 onwards.https://biopro-v9-test-gi.xanium.io/en/article/news/ehr-and-phr-digital-records-in-the-german-healthcare-system
Article - 24/01/2019 Scientists to combat antibiotic-resistant bacteria in wastewater In Germany, around 1,500 tonnes of antibiotics per year are administered to humans and animals. As a result, more and more bacteria are developing resistance to common antibiotics. As part of HyReKA, a cooperative project funded by the BMBF, scientists led by Professor Thomas Schwartz from the KIT are investigating how antibiotic-resistant pathogens spread and how they can be prevented from doing so.https://biopro-v9-test-gi.xanium.io/en/article/news/scientists-to-combat-antibiotic-resistant-bacteria-in-wastewater
Expert interview - 16/01/2019 Cybersecurity is an important issue for the pharmaceutical industry In an increasingly interconnected world, the pharmaceutical and biotechnology sectors need to be aware of cybersecurity threats in manufacturing. We talked about these threats with Holger Mettler who is in charge of computer system validation and cybersecurity at Exyte (formerly M + W), a global enterprise that designs, engineers and constructs complex manufacturing facilities and buildings for the life sciences industry.https://biopro-v9-test-gi.xanium.io/en/article/news/cybersecurity-is-an-important-issue-for-the-pharmaceutical-industry
Dossier - 28/08/2018 With molecular diagnostics to biomarker-based personalised therapy Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.https://biopro-v9-test-gi.xanium.io/en/article/dossier/with-molecular-diagnostics-to-biomarker-based-personalised-therapy
High-tech - 20/10/2016 Industry 4.0 in the medical technology and pharmaceutical industry sectors The digitalisation of industry affects the entire value chain. From individual products to digitising workflows in companies and connecting companies with clients and service providers via the Internet of Things – Industry 4.0 makes completely new manufacturing processes possible and requires new and specific business models.https://biopro-v9-test-gi.xanium.io/en/article/dossier/industry-40-in-the-medical-technology-and-pharmaceutical-industry-sectors
The Baden-Württemberg healthcare industry Infrastructure https://biopro-v9-test-gi.xanium.io/en/location/infrastructure
The Baden-Württemberg healthcare industry At a glance https://biopro-v9-test-gi.xanium.io/en/facts-and-figures
The Baden-Württemberg healthcare industry The pharmaceutical industry https://biopro-v9-test-gi.xanium.io/en/location/pharma
Dossier - 19/08/2013 Telemedicine advances in high-tech healthcare Increasing average longevity, the growing number of chronic diseases and health economy issues are all generating an ever-increasing demand for inexpensive therapy options that are not time - or location dependent. Telemedicine has been offering advanced solutions for a broad range of medical and health issues. Despite this progress, the use of telecommunication and information technologies in the provision of remote healthcare services appears…https://biopro-v9-test-gi.xanium.io/en/article/dossier/telemedicine-advances-in-high-tech-healthcare
Dossier - 26/11/2012 Genetic diagnostics technology reaches the limits of what is medically reasonable Rapid progress in sequencing technologies is poised to set the imagination of biomedical researchers on fire. Experts now believe that progress is about to make possible what seemed to be utopian a few years ago – it seems likely that it will soon be possible to sequence the human genome in only a few minutes and store and automatically analyse it using tiny automates. However, is everything that is technically feasible also reasonable?https://biopro-v9-test-gi.xanium.io/en/article/dossier/genetic-diagnostics-technology-reaches-the-limits-of-what-is-medically-reasonable
Dossier - 10/09/2012 Horizon 2020 the EU framework programme for research and innovation a boost for top-level research in Europe In the face of the ongoing financial crisis Europe is working on a new research strategy that is aimed at creating new economic growth and jobs. The new EU framework programme for research and innovation Horizon 2020 replaces the 7th Framework Programme FP7 and will run from 2014 with a budget of 80 billion. In July 2012 Brussels launched the final FP7 calls for proposals for 2013 that offer numerous market-based instruments designed to bridge…https://biopro-v9-test-gi.xanium.io/en/article/dossier/horizon-2020-the-eu-framework-programme-for-research-and-innovation-a-boost-for-top-level-research-i
Dossier - 18/06/2012 Biobanks treasure chests for biomedical research The Research Committee at the German Bundestag, the Office of Technology Assessment at the German Bundestag and the German Ethics Council are all interested in this biomedical research tool, which is both necessary and meaningful. However, opinions with regard to the ethical, legal and technical approach to biobanks differ. Since March 2012 it has become absolutely clear that Germany will not pass a biobanking law during the current mandate. https://biopro-v9-test-gi.xanium.io/en/article/dossier/biobanks-treasure-chests-for-biomedical-research
